Gynecologic Oncology

Dual inhibition with letrozole and abemaciclib displayed response and survival benefits in patients with recurrent estrogen receptor–positive endometrioid endometrial cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for cemiplimab monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

The therapeutic DNA vaccine, GX-188E, in combination with pembrolizumab produced encouraging responses in patients with human papillomavirus 16- or 18-positive, recurrent or metastatic cervical cancer who did not respond to standard-of-care treatment.

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

The combination of TQB2450 plus anlotinib generated responses and showcased a manageable safety profile in patients with recurrent or metastatic advanced endometrial cancer, according to data from the phase 2 TQB2450 II 08 trial.

Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.

Intensity-modulated radiation therapy elicited durable efficacy and a favorable safety profile compared with conventional radiotherapy in patients with endometrial and cervical cancers who received postoperative pelvic radiation.

Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors, with landmark estimates at various time points underscoring stable progression-free survival benefits in responders.

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

A supplemental new drug application and a Type II variation has been submitted to the FDA and the European Medicines Agency, respectively, seeking the approval of rucaparib as frontline maintenance treatment in women with advanced ovarian cancer irrespective of biomarker status who have responded to first-line platinum-based chemotherapy.

First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Cemiplimab maintained an overall survival benefit vs chemotherapy as a second-line treatment for patients with recurrent or metastatic cervical cancer who received prior platinum-based chemotherapy.

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Pembrolizumab monotherapy and in combination with anlotinib demonstrated encouraging efficacy and safety when administered to patients with refractory or platinum-resistant recurrent high-grade serous ovarian cancer.

Toripalimab and concurrent chemoradiation elicited encouraging activity with acceptable tolerability in patients with locally advanced cervical cancer.

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.